Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trialSéverine Vermeire, Walter Reinisch, William J. Sandborn et al.|The Lancet|2017Cited by 198
Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn’s disease: report of the OPERA studyWilliam J. Sandborn, Geert D’Haens, Scott D. Lee et al.|Gut|2017Cited by 107
Long-term Safety and Efficacy of the Anti-MAdCAM-1 Monoclonal Antibody Ontamalimab [SHP647] for the Treatment of Ulcerative Colitis: The Open-label Study TURANDOT IIWalter Reinisch, Séverine Vermeire, Miles Sparrow et al.|Journal of Crohn s and Colitis|2021Cited by 34
901a A Randomized, Multicenter Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Anti-MAdCAM Antibody PF-00547659 (PF) in Patients With Moderate to Severe Ulcerative Colitis: Results of the TURANDOT StudyWalter Reinisch, Séverine Vermeire, William J. Sandborn et al.|Gastroenterology|2015Cited by 26
Anti-MAdCAM-1 Antibody (PF-00547659) for Active Refractory Crohn's Disease: Results of the OPERA studyGeert D’Haens, W. Sandborn, S. Lee et al.|Unknown|2015Cited by 16